ABZENA
Abzena’ s Cambridge facility
Abzena is working to further investment in its own intellectual property as well as its portfolio offerings, taking key challenges like improving yield and stability in its stride to ensure the delivery of value in the shortest possible timeframe.
By continuing to invest in technologies like ML and data science, Dave believes that Abzena will continue its approach leveraging technology to determine the best path to success.
“ AI is not going to take jobs,” Dave affirms.“ It needs quite a lot of help to be effective, but when it is effective, it’ s pretty amazing.” Dave is also quick to reiterate its ability to enhance – and how it will continue to in a way we may not be able to fathom yet.
“ It’ s helping us not only solve today’ s problems but adapt to solve tomorrow’ s future problems, too,” he adds.
Abzena’ s future will also centre on expanding its capabilities to better serve its clients and to improve in commercial production.“ With patients out in the world waiting on medicines, if we make a mistake then potentially they won’ t have access to it,” Dave concludes.“ We’ re hoping to bring in more scrutiny as there are people who rely on us to be there.
“ We are also always looking at growth and helping our clients be successful and move their therapies – so not only helping clients through the drug development clinical stages, but also delivering approved medications in a reliable, consistent fashion to patients globally.” abzena. com 17